AlloVir, Inc. (ALVR)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -69.78M |
| Shares Out | 65.11M |
| EPS (ttm) | -2.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $23.85 |
| Previous Close | $22.38 |
| Change ($) | 1.47 |
| Change (%) | 6.57% |
| Day's Open | 22.39 |
| Day's Range | 22.01 - 23.91 |
| Day's Volume | 171,799 |
| 52-Week Range | 18.15 - 48.96 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company's...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Globa...
AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-conc...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial resu...
The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster prese...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healt...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investi...
--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened imm...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demon...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62n...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Confere...
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support ...
Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Significantly Hig...
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients
Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initia...
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annua...
Stock of virus therapy biotech up more than 70% in just a few days
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of 18,6...
AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of 16,2...
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and hu... [Read more...]
| Industry Biotechnology | IPO Date Jul 30, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol ALVR |
Analyst Forecasts
According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 105.45% from the latest price.